We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

18 hedge funds and large institutions have $1.08M invested in Scinai Immunotherapeutics in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

73% more capital invested

Capital invested by funds: $623K → $1.08M (+$454K)

38% more funds holding

Funds holding: 13 → 18 (+5)

0% less ownership

Funds ownership: 0% → 0% (-0%)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
18
Holders Change
+5
Holders Change %
+38.46%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
1
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$140K
2
Citadel Advisors
Citadel Advisors
Florida
+$128K
3
Goldman Sachs
Goldman Sachs
New York
+$118K
4
VF
Virtu Financial
New York
+$79.9K
5
TPWA
TRUE Private Wealth Advisors
Oregon
+$52.4K

Top Sellers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
-$139K
2
Morgan Stanley
Morgan Stanley
New York
-$84.3K
3
Two Sigma Investments
Two Sigma Investments
New York
-$76K
4
Wells Fargo
Wells Fargo
California
-$3.49K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
1
State Street
Massachusetts
$296K +$29.7K +68 +10%
Morgan Stanley
2
Morgan Stanley
New York
$157K -$84.3K -193 -32%
HF
3
HRT Financial
New York
$121K +$140K +320 New
Citadel Advisors
4
Citadel Advisors
Florida
$111K +$128K +293 New
Goldman Sachs
5
Goldman Sachs
New York
$103K +$118K +270 New
VF
6
Virtu Financial
New York
$70K +$79.9K +183 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$52K – – –
TPWA
8
TRUE Private Wealth Advisors
Oregon
$46K +$52.4K +120 New
Two Sigma Advisers
9
Two Sigma Advisers
New York
$42K +$48.5K +111 New
AIM
10
ARK Investment Management
Florida
$37K -$139K -318 -76%
Credit Agricole
11
Credit Agricole
France
$16K +$18.3K +42 New
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$10K – – –
CAPTRUST Financial Advisors
13
CAPTRUST Financial Advisors
North Carolina
$5K – – –
NFG
14
Next Financial Group
Texas
$5K – – –
Wells Fargo
15
Wells Fargo
California
$3K -$3.49K -8 -47%
GRP
16
Global Retirement Partners
California
$2K – – –
RWB
17
RMR Wealth Builders
New Jersey
$1K – – –
Two Sigma Investments
18
Two Sigma Investments
New York
– -$76K -269 Closed
Barclays
19
Barclays
United Kingdom
– +$437 +1 New

SCNI Hedge Fund Activity: Q1 2021 in Review

18 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2021, worth a combined $1.08M — up 73% from $623K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new SCNI positions and 3 closed out — a net gain of 5 holders — while 1 added to existing stakes and 3 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $140K. The largest seller was ARK Investment Management, cutting an estimated $139K.

  • 18 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2021, up from 13 in Q4 2020.
  • Funds reported $1.08M of Scinai Immunotherapeutics stock for Q1 2021, up 73% quarter-over-quarter.
  • 8 funds opened new Scinai Immunotherapeutics positions in Q1 2021 and 3 closed out, a net change of +5 holders.
  • The largest Scinai Immunotherapeutics buyer in Q1 2021 was HRT Financial, an estimated $140K added.
  • The largest Scinai Immunotherapeutics seller in Q1 2021 was ARK Investment Management, an estimated $139K sold.

Based on aggregated 13F filings for Q1 2021.